Jones Trading Rates Tyra Biosciences (TYRA) buy, $56 Price Target

Jones Trading reaffirms its buy rating on Tyra Biosciences with a $56 price target, a 85.80% upside from the current price.

By TradeTexts Research Desk · Published Jun 17, 2026, 10:01 AM EDT · Updated Jun 23, 2026, 12:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Jones Trading rated Tyra Biosciences, Inc. ($TYRA) "buy" with a $56 price target on June 17, 2026.

Since the rating, $TYRA is up 4.5% after 1 week, up 10.5% after 1 month and down 36.3% to date (from the $29.07 close on Jun 17, 2026).

TYRA Tyra Biosciences, Inc.

$18.52 -30.87% year to date

Daily close · Oct 16, 2026

Key Points

Jones Trading reiterated its buy rating on Tyra Biosciences with a price target of $56 as of June 17, 2026.
Jones Trading's $56 price target implies 85.80% upside from Tyra Biosciences, Inc.'s ($TYRA) current $30.14 share price.
Tyra Biosciences, trading at $28.21, has a market cap of about $1.68 billion and a 52-week range of $8.98 to $40.65.
Insiders bought shares on May 28, 2026, and analysts maintain a strong buy consensus with a mean target price of $51.60.

Get $TYRA trade alerts by text

We text you when insiders, Congress or big funds trade $TYRA. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Tyra Biosciences, Inc. alert may contain errors. Disclosures

Jones Trading has reiterated its buy rating on Tyra Biosciences, Inc. (NasdaqGS: TYRA), setting a price target of $56. This update was made by analyst Nazerke Baimukan on June 17, 2026. Shares of Tyra Biosciences are currently trading around $28.21.

Other Institutional Activity in Tyra Biosciences

RA Capital Management, L.P. holds 12,198,625 shares valued at approximately $467.2 million without changing its position. FMR LLC significantly increased its holdings by 7,735,085 shares, ending with 7,747,648 shares worth about $296.7 million. Janus Henderson Group PLC added 955,147 shares, bringing its total to 3,890,589 shares valued at $148.9 million. Farallon Capital Management LLC also boosted its stake by 1,514,000 shares to a total of 3,580,818 shares, valued at around $137.1 million.

Tyra Biosciences, Inc. Stock Up 17.1%

Shares of Tyra Biosciences, Inc. (NasdaqGS: TYRA) are trading near $28.21. The company has a market capitalization of about $1.68 billion. Although it is not currently profitable, Tyra has a beta of 0.754, indicating it is less volatile than the broader market. The stock's 52-week range is between $8.98 and $40.65, with a 50-day moving average of $33.19 and a 200-day moving average of $26.01. The company boasts a strong liquidity position with a current ratio of 20.49 and a quick ratio of 20.05, alongside a low debt-to-equity ratio of 1.47.

12-month forecast

$TYRA price target

Tyra Biosciences, Inc. daily closes and this analyst's $56 target. Not advice.

Recent Earnings

Tyra Biosciences reported a net margin of 0.0% and a return on equity of -36.87%, indicating it is not yet profitable. The company's EPS was -$2.18. Investors are looking forward to the next earnings release, scheduled for August 13, 2026.

Insider Buying and Selling at Tyra Biosciences, Inc.

On May 28, 2026, several insiders, including Susan Moran, Jake Simson, Adele Gulfo, Robert More, and Stephen Michael Rothenberg, each purchased 13,160 shares of Tyra Biosciences. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

On June 17, 2026, Jones Trading reiterated its buy rating with a $56 price target. Previously, on June 10, B of A Securities maintained a buy rating with a $42 target. Earlier in the year, on April 15, Guggenheim initiated coverage with a buy rating and a $54 target, while Canaccord Genuity set a $50 target on April 6. The consensus among analysts is a strong buy, with a mean target price of $51.60 based on 11 opinions.

About Tyra Biosciences

Tyra Biosciences, Inc., headquartered in Carlsbad, California, is a clinical-stage biotechnology company focused on developing precision medicines for FGFR biology. Its SNÅP platform aids in designing drugs that predict genetic alterations, targeting oncology and genetically defined conditions. Tyra's lead product, FGFR3, is in clinical trials for treating metastatic urothelial carcinoma. The company also works on TYRA-300 for skeletal conditions and TYRA-200 and TYRA-430 for various cancers. Led by CEO Dr. Todd Harris, Tyra Biosciences employs 87 people.

Bottom Line

Tyra Biosciences is attracting attention with its innovative approach to precision medicine. The reiterated buy rating from Jones Trading highlights confidence in its future potential. While the company is not yet profitable, its promising pipeline and strategic insider buying are factors investors are watching closely. As always, remember that analyst ratings and 13F filings reflect past activity and may not represent current positions.